x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011867
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human CABIN1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | CABIN1 |
| UniProt No. | Q9Y6J0 |
| Gene ID | 23523 |
| Gene Description | Calcineurin binding protein CABIN1 was originally identified as an inhibitor of the calcium-dependent serine/threonine phosphatase, calcineurin. CABIN1 inhibits calcineurin signaling in T cells, regulating T cell receptor signaling, transcription, and apoptosis. CABIN1 represses myocyte enhancer factor 2 -mediated transcription by recruiting chromatin remodeling enzymes, and also negatively regulates the activity of the tumor suppressor p53. In response to genotoxic stress, CABIN1 is degraded and releases its inhibition of p53, allowing p53 to elicit cellular stress responses. CABIN1 is also involved in regulation of chromatin structure as part of the highly conserved HIRA/UBN1/CABIN1/ASF1A histone chaperone complex. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
